151
|
You D, Fukuzawa H, Sakakibara Y, Takanashi T, Ito Y, Maliyar GG, Motomura K, Nagaya K, Nishiyama T, Asa K, Sato Y, Saito N, Oura M, Schöffler M, Kastirke G, Hergenhahn U, Stumpf V, Gokhberg K, Kuleff AI, Cederbaum LS, Ueda K. Charge transfer to ground-state ions produces free electrons. Nat Commun 2017; 8:14277. [PMID: 28134238 PMCID: PMC5290264 DOI: 10.1038/ncomms14277] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2016] [Accepted: 12/09/2016] [Indexed: 11/09/2022] Open
Abstract
Inner-shell ionization of an isolated atom typically leads to Auger decay. In an environment, for example, a liquid or a van der Waals bonded system, this process will be modified, and becomes part of a complex cascade of relaxation steps. Understanding these steps is important, as they determine the production of slow electrons and singly charged radicals, the most abundant products in radiation chemistry. In this communication, we present experimental evidence for a so-far unobserved, but potentially very important step in such relaxation cascades: Multiply charged ionic states after Auger decay may partially be neutralized by electron transfer, simultaneously evoking the creation of a low-energy free electron (electron transfer-mediated decay). This process is effective even after Auger decay into the dicationic ground state. In our experiment, we observe the decay of Ne2+ produced after Ne 1s photoionization in Ne-Kr mixed clusters.
Collapse
Affiliation(s)
- D You
- Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Sendai 980-8577, Japan.,RIKEN SPring-8 Center, Kouto 1-1-1, Sayo, Hyogo 679-5148, Japan
| | - H Fukuzawa
- Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Sendai 980-8577, Japan.,RIKEN SPring-8 Center, Kouto 1-1-1, Sayo, Hyogo 679-5148, Japan
| | - Y Sakakibara
- Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Sendai 980-8577, Japan.,RIKEN SPring-8 Center, Kouto 1-1-1, Sayo, Hyogo 679-5148, Japan
| | - T Takanashi
- Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Sendai 980-8577, Japan.,RIKEN SPring-8 Center, Kouto 1-1-1, Sayo, Hyogo 679-5148, Japan
| | - Y Ito
- Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Sendai 980-8577, Japan.,RIKEN SPring-8 Center, Kouto 1-1-1, Sayo, Hyogo 679-5148, Japan
| | - G G Maliyar
- Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Sendai 980-8577, Japan.,RIKEN SPring-8 Center, Kouto 1-1-1, Sayo, Hyogo 679-5148, Japan
| | - K Motomura
- Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Sendai 980-8577, Japan.,RIKEN SPring-8 Center, Kouto 1-1-1, Sayo, Hyogo 679-5148, Japan
| | - K Nagaya
- RIKEN SPring-8 Center, Kouto 1-1-1, Sayo, Hyogo 679-5148, Japan.,Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - T Nishiyama
- RIKEN SPring-8 Center, Kouto 1-1-1, Sayo, Hyogo 679-5148, Japan.,Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - K Asa
- RIKEN SPring-8 Center, Kouto 1-1-1, Sayo, Hyogo 679-5148, Japan.,Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - Y Sato
- RIKEN SPring-8 Center, Kouto 1-1-1, Sayo, Hyogo 679-5148, Japan.,Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - N Saito
- RIKEN SPring-8 Center, Kouto 1-1-1, Sayo, Hyogo 679-5148, Japan.,National Metrology Institute of Japan, AIST, Tsukuba 305-8568, Japan
| | - M Oura
- RIKEN SPring-8 Center, Kouto 1-1-1, Sayo, Hyogo 679-5148, Japan
| | - M Schöffler
- RIKEN SPring-8 Center, Kouto 1-1-1, Sayo, Hyogo 679-5148, Japan.,Institute for Nuclear Physics, Johann Wolfgang Goethe University Frankfurt, Frankfurt 60438, Germany
| | - G Kastirke
- Institute for Nuclear Physics, Johann Wolfgang Goethe University Frankfurt, Frankfurt 60438, Germany
| | - U Hergenhahn
- Leibniz Institute of Surface Modification, Leipzig 04318, Germany.,Max-Planck-Institute for Plasma Physics, Greifswald 17491, Germany
| | - V Stumpf
- Theoretische Chemie, Physikalisch-Chemisches Institut, Universität Heidelberg, Heidelberg 69120, Germany
| | - K Gokhberg
- Theoretische Chemie, Physikalisch-Chemisches Institut, Universität Heidelberg, Heidelberg 69120, Germany
| | - A I Kuleff
- Theoretische Chemie, Physikalisch-Chemisches Institut, Universität Heidelberg, Heidelberg 69120, Germany
| | - L S Cederbaum
- Theoretische Chemie, Physikalisch-Chemisches Institut, Universität Heidelberg, Heidelberg 69120, Germany
| | - K Ueda
- Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Sendai 980-8577, Japan.,RIKEN SPring-8 Center, Kouto 1-1-1, Sayo, Hyogo 679-5148, Japan
| |
Collapse
|
152
|
Selvarajan V, Osato M, Nah GSS, Yan J, Chung TH, Voon DCC, Ito Y, Ham MF, Salto-Tellez M, Shimizu N, Choo SN, Fan S, Chng WJ, Ng SB. RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC. Leukemia 2017; 31:2219-2227. [PMID: 28119527 PMCID: PMC5629367 DOI: 10.1038/leu.2017.40] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2016] [Revised: 01/03/2017] [Accepted: 01/10/2017] [Indexed: 12/14/2022]
Abstract
RUNX3, runt-domain transcription factor, is a master regulator of gene expression in major developmental pathways. It acts as a tumor suppressor in many cancers but is oncogenic in certain tumors. We observed upregulation of RUNX3 mRNA and protein expression in nasal-type extranodal natural killer (NK)/T-cell lymphoma (NKTL) patient samples and NKTL cell lines compared to normal NK cells. RUNX3 silenced NKTL cells showed increased apoptosis and reduced cell proliferation. Potential binding sites for MYC were identified in the RUNX3 enhancer region. Chromatin immunoprecipitation-quantitative PCR revealed binding activity between MYC and RUNX3. Co-transfection of the MYC expression vector with RUNX3 enhancer reporter plasmid resulted in activation of RUNX3 enhancer indicating that MYC positively regulates RUNX3 transcription in NKTL cell lines. Treatment with a small-molecule MYC inhibitor (JQ1) caused significant downregulation of MYC and RUNX3, leading to apoptosis in NKTL cells. The growth inhibition resulting from depletion of MYC by JQ1 was rescued by ectopic MYC expression. In summary, our study identified RUNX3 overexpression in NKTL with functional oncogenic properties. We further delineate that MYC may be an important upstream driver of RUNX3 upregulation and since MYC is upregulated in NKTL, further study on the employment of MYC inhibition as a therapeutic strategy is warranted.
Collapse
Affiliation(s)
- V Selvarajan
- Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
| | - M Osato
- Cancer Science Institute of Singapore, National University of Singapore, Singapore.,International Research Center for Medical Sciences, Kumamoto University, Kumamoto, Japan
| | - G S S Nah
- Cancer Science Institute of Singapore, National University of Singapore, Singapore
| | - J Yan
- Cancer Science Institute of Singapore, National University of Singapore, Singapore
| | - T-H Chung
- Cancer Science Institute of Singapore, National University of Singapore, Singapore
| | - D C-C Voon
- Institute for Frontier Science Initiative, Kanazawa University, Japan.,Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
| | - Y Ito
- Cancer Science Institute of Singapore, National University of Singapore, Singapore
| | - M F Ham
- Department of Anatomical Pathology, Faculty of Medicine, University of Indonesia, West Java, Indonesia
| | - M Salto-Tellez
- Cancer Science Institute of Singapore, National University of Singapore, Singapore.,School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK
| | - N Shimizu
- Department of Virology, Tokyo Medical and Dental University, Tokyo, Japan
| | - S-N Choo
- Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
| | - S Fan
- Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
| | - W-J Chng
- Cancer Science Institute of Singapore, National University of Singapore, Singapore.,Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore
| | - S-B Ng
- Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.,Cancer Science Institute of Singapore, National University of Singapore, Singapore.,Department of Pathology, National University Hospital, National University Health System, Singapore
| |
Collapse
|
153
|
Terabayashi N, Matsumoto K, Takigami I, Ito Y. Treatment of Humeral Fracture after Shoulder Arthroplasty using Functional Brace: A Case Report. J Orthop Case Rep 2017; 6:3-5. [PMID: 28111621 PMCID: PMC5040565 DOI: 10.13107/jocr.2250-0685.402] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Introduction: A periprosthetic humeral fracture is rare after shoulder arthroplasty, and such cases have considerable problems. Patients with this kind of fracture are often complicated by osteopenia, other types of severe disease, or are elderly. Surgical treatment of this fracture type carries some risk, and surgeons may be unsure about the most appropriate approach to adopt. Case report: The present case occurred in a 78-year-old woman with an osteoporotic humeral bone, and chronic dislocation of shoulder after shoulder arthroplasty. There were many risk factors for revision surgery or ostheosynthesis. Therefore, we decided to treat the patient by functional bracing. Fortunately, complete radiographic union was confirmed at 17 weeks. She returned to daily life with good functional activity. Conclusion: In our opinion, it is acceptable to select functional bracing for periprosthetic humeral fractures after shoulder arthroplasty without stem loosening in elderly patients with an osteoporotic humeral bone.
Collapse
Affiliation(s)
- Nobuo Terabayashi
- Department of Orthopaedic Surgery, Gifu University Graduate School of Medicine, Gifu, Japan
| | - Kazu Matsumoto
- Department of Orthopaedic Surgery, Gifu University Graduate School of Medicine, Gifu, Japan
| | - Iori Takigami
- Department of Orthopaedic Surgery, Gifu University Graduate School of Medicine, Gifu, Japan
| | - Yoshiki Ito
- Department of Orthopaedic Surgery, Kizawa Memorial Hospital, Gifu, Japan
| |
Collapse
|
154
|
Tasaki M, Saito K, Nakagawa Y, Imai N, Ito Y, Aoki T, Kamimura M, Narita I, Tomita Y, Takahashi K. Acquired Downregulation of Donor-Specific Antibody Production After ABO-Incompatible Kidney Transplantation. Am J Transplant 2017; 17:115-128. [PMID: 27343838 DOI: 10.1111/ajt.13937] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2015] [Revised: 05/31/2016] [Accepted: 06/21/2016] [Indexed: 01/25/2023]
Abstract
The mechanism of long-term B cell immunity against donor blood group antigens in recipients who undergo ABO-incompatible (ABOi) living-donor kidney transplantation (LKTx) is unknown. To address this question, we evaluated serial anti-A and anti-B antibody titers in 50 adult recipients. Donor-specific antibody titers remained low (≤1:4) in 42 recipients (84%). However, antibodies against nondonor blood group antigens were continuously produced in recipients with blood type O. We stimulated recipients' peripheral blood mononuclear cells in vitro to investigate whether B cells produced antibodies against donor blood group antigens in the absence of graft adsorption in vivo. Antibodies in cell culture supernatant were measured using specific enzyme-linked immunosorbent assays (ELISAs). Thirty-five healthy volunteers and 57 recipients who underwent ABO-compatible LKTx served as controls. Antibody production in vitro against donor blood group antigens by cells from ABOi LKTx patients was lower than in the control groups. Immunoglobulin deposits were undetectable in biopsies of grafts of eight recipients with low antibody titers (≤1:4) after ABOi LKTx. One patient with blood type A1 who received a second ABOi LKTx from a type B donor did not produce B-specific antibodies. These findings suggest diminished donor-specific antibody production function in the setting of adult ABOi LKTx.
Collapse
Affiliation(s)
- M Tasaki
- Division of Urology, Department of Regenerative & Transplant Medicine, Niigata Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - K Saito
- Division of Urology, Department of Regenerative & Transplant Medicine, Niigata Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Y Nakagawa
- Division of Urology, Department of Regenerative & Transplant Medicine, Niigata Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - N Imai
- Division of Clinical Nephrology and Rheumatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
| | - Y Ito
- Division of Clinical Nephrology and Rheumatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
| | - T Aoki
- Division of Transfusion Medicine and Regenerative Medicine, Bioscience Medical Center, Niigata University Medical and Dental Hospital, Niigata, Japan
| | - M Kamimura
- Division of Transfusion Medicine and Regenerative Medicine, Bioscience Medical Center, Niigata University Medical and Dental Hospital, Niigata, Japan
| | - I Narita
- Division of Clinical Nephrology and Rheumatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
| | - Y Tomita
- Division of Urology, Department of Regenerative & Transplant Medicine, Niigata Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - K Takahashi
- Division of Urology, Department of Regenerative & Transplant Medicine, Niigata Graduate School of Medical and Dental Sciences, Niigata, Japan.,Niigata Prefecture Organ Transplant Promotion Foundation, Tokyo, Japan
| |
Collapse
|
155
|
Suzuki I, Matsumoto A, Ito Y, Yamada Y. Novel fast-sintered zirconia for chair-side dentistry. Dent Mater 2017. [DOI: 10.1016/j.dental.2017.08.154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
156
|
Takayama K, Ito Y, Kaneko H, Kataoka K, Sugita T, Maruko R, Hattori K, Ra E, Haga F, Terasaki H. Comparison of indocyanine green angiography and optical coherence tomographic angiography in polypoidal choroidal vasculopathy. Eye (Lond) 2017; 31:45-52. [PMID: 27813526 PMCID: PMC5233943 DOI: 10.1038/eye.2016.232] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2016] [Accepted: 09/14/2016] [Indexed: 11/08/2022] Open
Abstract
PurposeTo compare optical coherence tomographic angiography (OCTA) and indocyanine green angiography (ICGA) images for detecting polypoidal lesions (PLs) and branching vascular networks (BVNs), and to measure the polypoidal areas (PAs) in patients with polypoidal choroidal vasculopathy (PCV).MethodsAll patients underwent ICGA, optical coherence tomography (OCT), and OCTA. We compared the detection sensitivity for PL and BVN, as evaluated by the ICGA and OCTA images. Furthermore, PA measured by ICGA was divided into two groups: one in which the area could be measured by OCTA (ICGA+OCTA+) and the other in which the area could not be measured by OCTA (ICGA+OCTA-).ResultsTwenty-one consecutive eyes of 21 patients (mean age, 73.8±9.8 years) were included. ICGA detected PL in all eyes (100%), whereas OCTA detected PL in 16 eyes (75.2%); ICGA detected BVN in 15 eyes (71.4%), whereas OCTA detected BVN in 20 eyes (95.2%). The mean PA in ICGA+OCTA+ and ICGA+OCTA- was 0.24±0.04 and 0.14±0.01 mm2, respectively; a significant difference was observed between ICGA+OCTA+ PA and ICGA+OCTA- PA (P<0.0001). In addition, the mean PA in the ICGA+OCTA+ group measured by ICGA and OCTA was 0.24±0.04 was 0.19±0.04 mm2, respectively; these values were significantly different (P=0.0046).ConclusionsOCTA might detect more BVNs and fewer PLs compared with ICGA, and PL detected by OCTA might be smaller than those detected by ICGA.
Collapse
Affiliation(s)
- K Takayama
- Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Y Ito
- Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - H Kaneko
- Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - K Kataoka
- Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Sugita
- Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - R Maruko
- Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - K Hattori
- Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - E Ra
- Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - F Haga
- Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - H Terasaki
- Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
157
|
Wakai E, Kanemura T, Kondo H, Hirakawa Y, Ito Y, Serizawa H, Kawahito Y, Higashi T, Suzuki A, Fukada S, Furuya K, Esaki K, Yagi J, Tsuji Y, Ito T, Niitsuma S, Yoshihashi-Suzuki S, Watanabe K, Furukawa T, Groeschel F, Micciche G, Manorri S, Favuzza P, Nitti F, Heidinger R, Terai T, Horiike H, Sugimoto M, Ohira S, Knaster J. Engineering validation for lithium target facility of the IFMIF under IFMIF/EVEDA project. Nuclear Materials and Energy 2016. [DOI: 10.1016/j.nme.2016.05.012] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
158
|
Noura S, Ohue M, Hasegawa J, Hirota M, Matsumura T, Ito Y, Miyoshi N, Kobayashi H, Kotake K, Sugihara K. 177P New staging system for colorectal cancer patients with synchronous peritoneal metastasis in accordance with the Japanese Classification of Colorectal Carcinoma: A multi-institutional study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw581.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
159
|
Fukada I, Ito Y, Shibayama T, Kobayashi K, Teruya N, Takahashi S, Horii R, Akiyama F, Iwase T, Toi M, Ohno S. 89P Questionnaire survey on patients’ preference for orally disintegrating tablets or granules of S-1 in postoperative adjuvant treatment for breast cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw575.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
160
|
Noura S, Ohue M, Hasegawa J, Hirota M, Matsumura T, Ito Y, Miyoshi N, Kobayashi H, Kotake K, Sugihara K. 177P New staging system for colorectal cancer patients with synchronous peritoneal metastasis in accordance with the Japanese Classification of Colorectal Carcinoma: A multi-institutional study. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00335-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
161
|
Fukada I, Ito Y, Shibayama T, Kobayashi K, Teruya N, Takahashi S, Horii R, Akiyama F, Iwase T, Toi M, Ohno S. 89P Questionnaire survey on patients' preference for orally disintegrating tablets or granules of S-1 in postoperative adjuvant treatment for breast cancer. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00249-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
162
|
Qiu HJ, Chen LY, Ito Y, Kang JL, Guo XW, Liu P, Kashani H, Hirata A, Fujita T, Chen MW. An ultrahigh volumetric capacitance of squeezable three-dimensional bicontinuous nanoporous graphene. Nanoscale 2016; 8:18551-18557. [PMID: 27782251 DOI: 10.1039/c5nr08852f] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Graphene with a large specific surface area and high conductivity has a large specific capacitance. However, its volumetric capacitance is usually very low because the restacking of 2D graphene sheets leads to the loss of the large ion-accessible surface area. Here we report squeezable bicontinuous nanoporous nitrogen-doped graphene, which is extremely flexible and can tolerate large volume contraction by mechanical compression without the face-to-face restacking occurring. The compressed nanoporous N-doped graphene with a large ion accessible surface area and high conductivity shows an ultrahigh volumetric capacitance of ∼300 F cm-3 together with excellent cycling stability and high rate performance.
Collapse
Affiliation(s)
- H-J Qiu
- WPI Advanced Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan. and School of Chemistry and Chemical Engineering, Chongqing University, Chongqing 400044, China
| | - L Y Chen
- WPI Advanced Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan.
| | - Y Ito
- WPI Advanced Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan.
| | - J L Kang
- WPI Advanced Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan.
| | - X W Guo
- WPI Advanced Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan.
| | - P Liu
- WPI Advanced Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan.
| | - H Kashani
- WPI Advanced Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan.
| | - A Hirata
- WPI Advanced Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan.
| | - T Fujita
- WPI Advanced Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan.
| | - M W Chen
- WPI Advanced Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan. and State Key Laboratory of Metal Matrix Composites, School of Materials Science and Engineering, Shanghai Jiao Tong University, Shanghai 200030, China and CREST, Japan Science and Technology Agency, Saitama 332-0012, Japan
| |
Collapse
|
163
|
Fudeyasu K, Kawae T, Fukuhara K, Iwaki D, Nakashima Y, Ueda K, Ito Y, Hiramatsu A, Kimura H. The effect of liver dysfunction on muscle strength in liver disease patients. Physiotherapy 2016. [DOI: 10.1016/j.physio.2016.10.359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
164
|
Tokuzawa T, Kisaki M, Nagaoka K, Tsumori K, Ito Y, Ikeda K, Nakano H, Osakabe M, Takeiri Y, Kaneko O. Upgraded millimeter-wave interferometer for measuring the electron density during the beam extraction in the negative ion source. Rev Sci Instrum 2016; 87:11E105. [PMID: 27910614 DOI: 10.1063/1.4959841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
The upgraded millimeter-wave interferometer with the frequency of 70 GHz is installed on a large-scaled negative ion source. Measurable line-averaged electron density is from 2 × 1015 to 3 × 1018 m-3 in front of the plasma grid. Several improvements such as the change to shorter wavelength probing with low noise, the installation of special ordered horn antenna, the signal modulation for a high accuracy digital phase detection, the insertion of insulator, and so on, are carried out for the measurement during the beam extraction by applying high voltage. The line-averaged electron density is successfully measured and it is found that it increases linearly with the arc power and drops suddenly at the beam extraction.
Collapse
Affiliation(s)
- T Tokuzawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - M Kisaki
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - K Nagaoka
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - K Tsumori
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - Y Ito
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - K Ikeda
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - H Nakano
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - M Osakabe
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - Y Takeiri
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki 509-5292, Japan
| | - O Kaneko
- National Institutes of Natural Sciences, 4-3-13 Toranomon, Minato-ku, Tokyo 105-0001, Japan
| |
Collapse
|
165
|
Tanabe K, Yoshikawa T, Oshima T, Miyagi Y, Morita S, Nishikawa K, Ito Y, Matsui T, Kimura Y, Aoyama T, Hayashi T, Ogata T, Cho H, Tuburaya A, Sakamoto J. Biomarker analysis to predict the pathological response of locally advanced gastric cancer to neoadjuvant chemotherapy: an exploratory study of the randomized phase II COMPASS trial. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw363.35] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
166
|
Nishimura Y, Kodaira T, Ito Y, Tsuchiya K, Murakami Y, Saitoh J, Akimoto T, Nakata K, Yoshimura M, Teshima T, Toshiyasu T, Ota Y, Ishikawa K, Shimizu H, Minemura T, Ishikura S, Shibata T, Nakamura K, Shibata T, Hiraoka M. A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) with Chemotherapy for Locoregionally Advanced Nasopharyngeal Cancer (NPC) (JCOG1015): Acute Toxicity and Treatment Compliance. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1467] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
167
|
Nakajima N, Oguchi M, Kumai Y, Yoshida M, Iwase T, Ito Y, Akiyama F, Ohno S. Clinical Outcome and Prognostic Factors in Locally Advanced Breast Cancer Patients Treated With Neoadjuvant Chemotherapy Followed by Surgery and Postmastectomy Radiation Therapy. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
168
|
Sekii S, Murakami N, Nakamura S, Kashihara T, Kobayashi K, Harada K, Kitaguchi M, Takahashi K, Inaba K, Igaki H, Ito Y, Itami J. Supplementary Bladder Reference Point of High-Dose-Rate Intracavitary Brachytherapy for Cervical Cancer: Feedback 3-Dimension to 2-Dimension. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
169
|
Hashimoto M, Ito Y, Takahashi R, Nakajima M, Matsubayashi F, Saotome S, Kitamura N, Sato T, Kozuka T, Oguchi M. Four-Dimensional Dose Reconstruction for Lung Cancer in Volumetric Modulated Arc Therapy. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.2160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
170
|
Kobayashi K, Ito Y, Shibayama T, Fukada I, Ishizuka N, Horii R, Takahashi S, Akiyama F, Iwase T, Ohno S. Eribulin mesylate may improve the sensitivity of endocrine therapy in metastatic breast cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw365.23] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
171
|
Ito Y, Kato K, Hashimoto J, Akimoto T, Katano S, Saito Y, Igaki H. Phase 2 Study of Neoadjuvant Chemoradiation Therapy With Cisplatin Plus 5-Fluorouracil and Elective Nodal Irradiation Followed by Surgery for Stage II/III Esophageal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
172
|
Ioka T, Fukutomi A, Mizusawa J, Katayama H, Nakamura S, Ito Y, Hiraoka N, Ueno M, Ikeda M, Sugimori K, Shimizu K, Okusaka T, Ozaka M, Yanagimoto H, Nakamori S, Azuma T, Hosokawa A, Sata N, Mine T, Furuse J. Randomized phase II study of S-1 and concurrent radiotherapy with versus without induction chemotherapy of gemcitabine for locally advanced pancreatic cancer (LAPC): Final analysis of JCOG1106. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.13] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
173
|
Huang C, Jiang D, Francisco D, Berman R, Wu Q, Ledford JG, Moore CM, Ito Y, Stevenson C, Munson D, Li L, Kraft M, Chu HW. Tollip SNP rs5743899 modulates human airway epithelial responses to rhinovirus infection. Clin Exp Allergy 2016; 46:1549-1563. [PMID: 27513438 DOI: 10.1111/cea.12793] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2016] [Revised: 07/15/2016] [Accepted: 07/19/2016] [Indexed: 12/24/2022]
Abstract
BACKGROUND Rhinovirus (RV) infection in asthma induces varying degrees of airway inflammation (e.g. neutrophils), but the underlying mechanisms remain unclear. OBJECTIVE The major goal was to determine the role of genetic variation [e.g. single nucleotide polymorphisms (SNPs)] of Toll-interacting protein (Tollip) in airway epithelial responses to RV in a type 2 cytokine milieu. METHODS DNA from blood of asthmatic and normal subjects was genotyped for Tollip SNP rs5743899 AA, AG and GG genotypes. Human tracheobronchial epithelial (HTBE) cells from donors without lung disease were cultured to determine pro-inflammatory and antiviral responses to IL-13 and RV16. Tollip knockout and wild-type mice were challenged with house dust mite (HDM) and infected with RV1B to determine lung inflammation and antiviral response. RESULTS Asthmatic subjects carrying the AG or GG genotype (AG/GG) compared with the AA genotype demonstrated greater airflow limitation. HTBE cells with AG/GG expressed less Tollip. Upon IL-13 and RV16 treatment, cells with AG/GG (vs. AA) produced more IL-8 and expressed less antiviral genes, which was coupled with increased NF-κB activity and decreased expression of LC3, a hallmark of the autophagic pathway. Tollip co-localized and interacted with LC3. Inhibition of autophagy decreased antiviral genes in IL-13- and RV16-treated cells. Upon HDM and RV1B, Tollip knockout (vs. wild-type) mice demonstrated higher levels of lung neutrophilic inflammation and viral load, but lower levels of antiviral gene expression. CONCLUSIONS AND CLINICAL RELEVANCE Our data suggest that Tollip SNP rs5743899 may predict varying airway response to RV infection in asthma.
Collapse
Affiliation(s)
- C Huang
- Department of Medicine, National Jewish Health, Denver, CO, USA
| | - D Jiang
- Department of Medicine, National Jewish Health, Denver, CO, USA
| | - D Francisco
- Department of Medicine, University of Arizona College of Medicine, Tucson, AZ, USA
| | - R Berman
- Department of Medicine, National Jewish Health, Denver, CO, USA
| | - Q Wu
- Department of Medicine, National Jewish Health, Denver, CO, USA
| | - J G Ledford
- Department of Medicine, University of Arizona College of Medicine, Tucson, AZ, USA
| | - C M Moore
- Department of Medicine, National Jewish Health, Denver, CO, USA
| | - Y Ito
- Department of Medicine, National Jewish Health, Denver, CO, USA
| | - C Stevenson
- Department of Medicine, National Jewish Health, Denver, CO, USA
| | - D Munson
- Department of Medicine, National Jewish Health, Denver, CO, USA
| | - L Li
- Department of Biological Sciences, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA
| | - M Kraft
- Department of Medicine, University of Arizona College of Medicine, Tucson, AZ, USA
| | - H W Chu
- Department of Medicine, National Jewish Health, Denver, CO, USA
| |
Collapse
|
174
|
Kumagai S, Ishida T, Tachibana H, Ito A, Ito Y, Hashimoto T. Polybacterial aetiology and outcomes in patients with community-acquired pneumonia. Int J Tuberc Lung Dis 2016; 20:129-35. [PMID: 26688539 DOI: 10.5588/ijtld.15.0353] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
SETTING Community-acquired pneumonia (CAP) is a common cause of morbidity and mortality worldwide. While interactions among bacterial pathogens in the respiratory tract have been studied, the impact of polybacterial aetiology on mortality has not been fully elucidated. OBJECTIVE To investigate the impact of polybacterial aetiology on mortality, prevalence, microbial patterns and clinical characteristics among CAP patients. DESIGN Retrospective data analysis. RESULTS Bacterial aetiology was established in 711 (46.0%) of 1544 enrolled hospitalised CAP patients. Of these, polybacterial aetiology was identified in 89 (12.5%): Streptococcus pneumoniae was the most frequently identified pathogen (n = 55, 61.8%). The most prevalent microbial combination was S. pneumoniae and Haemophilus influenzae (n = 19, 21.3%). Alcoholism and lack of previous antibiotic therapy were independent predictors of polybacterial aetiology. The proportion of patients with severe pneumonia was significantly higher in the polybacterial aetiology group than in the monobacterial group. Multivariate analysis showed that polybacterial aetiology was a predictor of 30-day mortality (OR 2.14, 95%CI 1.07-4.24, P = 0.030), independently of severe pneumonia status, pneumonia severity index, chronic obstructive pulmonary disease and inappropriate empirical therapy. CONCLUSION Polybacterial CAP tends to advance in severity, and indicates adverse outcomes.
Collapse
Affiliation(s)
- S Kumagai
- Department of Respiratory Medicine, Ohara Memorial Kurashiki Healthcare Foundation, Kurashiki Central Hospital, Kurashiki, Japan
| | - T Ishida
- Department of Respiratory Medicine, Ohara Memorial Kurashiki Healthcare Foundation, Kurashiki Central Hospital, Kurashiki, Japan
| | - H Tachibana
- Department of Respiratory Medicine, Ohara Memorial Kurashiki Healthcare Foundation, Kurashiki Central Hospital, Kurashiki, Japan
| | - A Ito
- Department of Respiratory Medicine, Ohara Memorial Kurashiki Healthcare Foundation, Kurashiki Central Hospital, Kurashiki, Japan
| | - Y Ito
- Department of Respiratory Medicine, Ohara Memorial Kurashiki Healthcare Foundation, Kurashiki Central Hospital, Kurashiki, Japan
| | - T Hashimoto
- Department of Respiratory Medicine, Ohara Memorial Kurashiki Healthcare Foundation, Kurashiki Central Hospital, Kurashiki, Japan
| |
Collapse
|
175
|
Satoh N, Ikaida M, Ito Y. Development of a novel homogeneous assay for remnant lipoproteins. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
176
|
Kato K, Matsumura Y, Yamamoto M, Nagao M, Ito Y, Takakura S, Ichiyama S. Erratum to: Seasonal trend and clinical presentation of Bacillus cereus bloodstream infection: association with summer and indwelling catheter. Eur J Clin Microbiol Infect Dis 2016; 35:875-83. [PMID: 27010814 DOI: 10.1007/s10096-016-2618-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Bacillus cereus, an opportunistic pathogen, can cause fatal infection. However, B. cereus bloodstream infections (BSIs) have not been well characterised. From 2008 to 2013, B. cereus isolates from all of the specimens and patients with B. cereus BSIs were identified. Environmental samples were collected to detect B. cereus contamination. We also characterised the clinical presentation of B. cereus BSI through analyses of risk factors for BSI and mortality. A total of 143 clinical B. cereus isolates was detected. Fifty-one patients with nosocomial infections were diagnosed as B. cereus BSI, and 37 had contaminated blood cultures. The number of B. cereus isolates and BSI patients was significantly greater from June to September than from January to April (3.4 vs. 1.0 per month and 1.4 vs. 0.2, respectively). All BSIs were nosocomial and related to central or peripheral vascular catheter. Urinary catheter [odds ratio (OR) 6.93, 95 % confidence interval (CI) 2.40-20.0] was the independent risk factor associated with BSI patients when compared to patients regarded as contaminated. In-hospital mortality among BSI patients was 20 % and was associated with urinary catheter (OR 12.3, 95 % CI 0.67-225, p=0.045) and higher Charlson index (OR 1.99, 95 % CI 1.26-3.12). The number of B. cereus isolates and BSI increased during summer. Inpatients with indwelling vascular or urinary catheters should be carefully monitored for potential B. cereus BSIs.
Collapse
Affiliation(s)
- K Kato
- Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan
| | - Y Matsumura
- Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan.
| | - M Yamamoto
- Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan
| | - M Nagao
- Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan
| | - Y Ito
- Department of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - S Takakura
- Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan
| | - S Ichiyama
- Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan
| |
Collapse
|
177
|
Abstract
Radical surgery for thoracic oesophageal cancer is highly invasive and often leads to respiratory complications; thoracoscopic surgery is a less-invasive alternative. We examined the need for chest physical therapy (CPT) after thoracoscopic oesophagectomy. Thirty-six consecutive patients, randomly selected for either thoracotomy or thoracoscopic surgery, were included in a randomized clinical trial and received CPT under the same protocol. During short-term post-operative follow-up, both groups showed a marked reduction in respiratory function and responded to CPT to the same extent, although 2 weeks after surgery some parameters of respiratory function were significantly higher in the thoracoscopy group. Thoracoscopic surgery has been reported to be less invasive than standard thoracotomy, but our results suggest that the procedure is also invasive with respect to respiratory function and that CPT should be performed before and after thoracoscopic surgery.
Collapse
Affiliation(s)
- T Nakatsuchi
- Division of Rehabilitation Medicine, Osaka City University Medical School, Osaka, Japan
| | | | | | | | | |
Collapse
|
178
|
Tamatani S, Ito Y, Koike T, Abe H, Kumagai T, Kurashima A, Koizumi T, Takeuchi S, Tanaka R. Efficacy of Diluted NBCA Mixture for Embolization of Arteriovenous Malformations. Interv Neuroradiol 2016; 5 Suppl 1:161-5. [DOI: 10.1177/15910199990050s129] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/1999] [Accepted: 09/30/1999] [Indexed: 11/17/2022] Open
Abstract
The purpose of this study is to evaluate the efficacy and problems of the embolization for cerebral arteriovenous malformations (AVMs) with diluted cyanoacrylate adhesives. Twelve consecutive AVM cases were treated with N-butyl-2-cyanoacrylate (NBCA) glues between January 1997 and July 1998. The mean age of the patients was 37 years old. Intracerebral hemorrhage was the presenting symptom in seven cases, seizure in three, headache in one and mental deterioration in one. According to the classification of Spetzler and Martin, seven were Grade 11, five were Grade III. We used a mixture of NBCA (normally 25% Histoacryl, 75% Ethidol) for embolization. Microcatheter was navigated into the nidus and the tip of the catheter was set in a wedged position. Then the glue was injected using complete column technique. Nineteen sessions of embolization were performed in 12 patients. The mean volume of each nidus was reduced from 22.5 ml to 3.4 ml (85%) after embolization. Four cases were cured by embolization alone. Surgical resection was performed after embolization without any residual nidus in three cases. Five were treated with stereotactic radiosurgery following embolization. One was completely cured in 18 months after and the other four have been decreasing their sizes of nidus. One case was suffered from delayed intracerebral hemorrhage three days after embolization, and resulted in mild hemiparesis and memory disturbance. The others had no complications and were clinically improved or unchanged after embolization. It is possible to embolize the nidus of AVMs more accurately and safely with diluted mixture of NBCA, compared with the method using relatively higher concentration of NBCA glues. This technique is useful and effective method for the treatment of AVMs.
Collapse
Affiliation(s)
| | | | - T. Koike
- Department of Neurosurgery, Niigata City General Hospital; Niigata
| | | | | | | | | | | | | |
Collapse
|
179
|
Favuzza P, Antonelli A, Furukawa T, Groeschel F, Hedinger R, Higashi T, Hirakawa Y, Iijima M, Ito Y, Kanemura T, Knaster J, Kondo H, Miccichè G, Nitti F, Ohira S, Severi M, Sugimoto M, Suzuki A, Traversi R, Wakai E. Round Robin test for the determination of nitrogen concentration in solid Lithium. Fusion Engineering and Design 2016. [DOI: 10.1016/j.fusengdes.2016.03.026] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
180
|
Maruki Y, Ueno H, Sasaki M, Sakamoto Y, Kondo S, Morizane C, Ito Y, Okusaka T. P-119 Chemoradiotherapy versus chemotherapy alone for unresectable locally advanced pancreatic cancer: a retrospective cohort study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw199.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
181
|
Ogawa H, Matsumoto K, Ito Y, Kawashima K, Takigami I, Akiyama H. Indirect Popliteal Artery Transections in Revision Total Knee Arthroplasty A Case Report. Bull Hosp Jt Dis (2013) 2016; 74:168-171. [PMID: 27281324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Popliteal artery injury in total knee arthroplasty (TKA) is rare but a devastating complication with consequence from transient bleeding to death. We report a case of 83-yearold woman suffering from an unusual early postoperative indirect popliteal artery transection in revision TKA for an infected knee. This injury was triggered by surgical correction of stiffened and distorted soft tissue, which resulted in excessive tensioning and eventual indirect transection of the artery. To avoid this devastating complication, early elimination of infection concomitant with perioperative maintenance of the normal anatomy of the knee is important.
Collapse
|
182
|
Tamura M, Ito Y, Sakurai H, Mizumoto M, Kamizawa S, Murayama S, Yamashita H, Takao S, Suzuki R, Shirato H. SU-F-T-202: An Evaluation Method of Lifetime Attributable Risk for Comparing Between Proton Beam Therapy and Intensity Modulated X-Ray Therapy for Pediatric Cancer Patients by Averaging Four Dose-Response Models for Carcinoma Induction. Med Phys 2016. [DOI: 10.1118/1.4956339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
183
|
Wallace LM, Webb SC, Ito Y, Mochizuki K, Hino R, Henrys S, Schwartz SY, Sheehan AF. Slow slip near the trench at the Hikurangi subduction zone, New Zealand. Science 2016; 352:701-4. [DOI: 10.1126/science.aaf2349] [Citation(s) in RCA: 198] [Impact Index Per Article: 24.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2016] [Accepted: 03/25/2016] [Indexed: 11/02/2022]
|
184
|
Kumai Y, Oguchi M, Miyagi Y, Ito Y, Iwase T, Akiyama F, Yoshida K, Harada A, Okubo H, Asari T, Murofushi K, Toshiyasu T, Kozuka T, Sumi M. EP-1164: Outcomes of postmastectomy radiotherapy in patients with 1 to 3 positive nodes in single institute. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32414-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
185
|
Lavine SD, Cockroft K, Hoh B, Bambakidis N, Khalessi AA, Woo H, Riina H, Siddiqui A, Hirsch JA, Chong W, Rice H, Wenderoth J, Mitchell P, Coulthard A, Signh TJ, Phatorous C, Khangure M, Klurfan P, terBrugge K, Iancu D, Gunnarsson T, Jansen O, Muto M, Szikora I, Pierot L, Brouwer P, Gralla J, Renowden S, Andersson T, Fiehler J, Turjman F, White P, Januel AC, Spelle L, Kulcsar Z, Chapot R, Spelle L, Biondi A, Dima S, Taschner C, Szajner M, Krajina A, Sakai N, Matsumaru Y, Yoshimura S, Ezura M, Fujinaka T, Iihara K, Ishii A, Higashi T, Hirohata M, Hyodo A, Ito Y, Kawanishi M, Kiyosue H, Kobayashi E, Kobayashi S, Kuwayama N, Matsumoto Y, Miyachi S, Murayama Y, Nagata I, Nakahara I, Nemoto S, Niimi Y, Oishi H, Satomi J, Satow T, Sugiu K, Tanaka M, Terada T, Yamagami H, Diaz O, Lylyk P, Jayaraman MV, Patsalides A, Gandhi CD, Lee SK, Abruzzo T, Albani B, Ansari SA, Arthur AS, Baxter BW, Bulsara KR, Chen M, Delgado Almandoz JE, Fraser JF, Heck DV, Hetts SW, Hussain MS, Klucznik RP, Leslie-Mawzi TM, Mack WJ, McTaggart RA, Meyers PM, Mocco J, Prestigiacomo CJ, Pride GL, Rasmussen PA, Starke RM, Sunenshine PJ, Tarr RW, Frei DF, Ribo M, Nogueira RG, Zaidat OO, Jovin T, Linfante I, Yavagal D, Liebeskind D, Novakovic R, Pongpech S, Rodesch G, Soderman M, terBrugge K, Taylor A, Krings T, Orbach D, Biondi A, Picard L, Suh DC, Tanaka M, Zhang HQ. Training Guidelines for Endovascular Ischemic Stroke Intervention: An International Multi-Society Consensus Document. AJNR Am J Neuroradiol 2016; 37:E31-4. [PMID: 26892982 DOI: 10.3174/ajnr.a4766] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
186
|
Fukada I, Araki K, Kobayashi K, Gomi N, Horii R, Akiyama F, Takahashi S, Iiwase T, Ohno S, Ito Y. Abstract P4-02-13: The pattern of tumor shrinkage is associated with prognosis in low grade luminal early breast cancer during neoadjuvant chemotherapy. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-02-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: In neoadjuvant chemotherapy (NAC) for early breast cancer, the pathological response rate in estrogen receptor (ER)-positive tumors has been low in comparison with those of ER-negative tumors. Therefore, surrogate makers other than the pCR rate are needed during NAC for luminal breast cancer. Using MRI, we analyzed the patterns of tumor shrinkage after NAC as a surrogate prognostic factor in low grade luminal breast cancer. METHODS: Of 854 patients who had received NAC in a single institute from Jan. 2000 to Dec. 2009, 183 patients with low grade luminal breast cancer were retrospectively evaluated for this study. They were defined as ER and/or PgR positive in more than 10% of cancer cells and HER2 negative (IHC 0, 1+ or FISH <2.0) with nuclear grade 1 and 2. RESULTS: The median observation period was 67.9 months following surgery, and recurrence was observed in 31 patients (16.9%). The median age was 49 (22-76) years. One hundred eighty patients received anthracycline-containing chemotherapy, and 158 received taxane. There were 16 deaths (8.7%) related to breast cancer. We categorized the patterns of tumor shrinkage by MRI into 6 types: concentric shrinkage (CS), diffuse decrease (DD), reduction to small foci (RSF), decrease of intensity only (DIO), no change (NC), and enlargement (EL). According to our categorization, CS occurred in 97 (53.0%), RSF in 7 (3.8%), DD in 62 (33.9%), DIO in 7 (3.8%), NC in 5 (2.7%), and EL in 5 (2.7%). As expected, there were statistically significant differences in both the median DFS and OS in each pattern of tumor shrinkage (p <0.001 and p=0.001, respectively); in particular, the CS pattern had excellent prognosis. Multivariate analysis demonstrated that concentric shrinkage was the only significant good prognostic factor for OS (p=0.015). CONCLUSIONS: Tumor shrinkage patterns as revealed by MRI could be important surrogate prognostic factors for NAC in early low grade luminal breast cancer.
Citation Format: Fukada I, Araki K, Kobayashi K, Gomi N, Horii R, Akiyama F, Takahashi S, Iiwase T, Ohno S, Ito Y. The pattern of tumor shrinkage is associated with prognosis in low grade luminal early breast cancer during neoadjuvant chemotherapy. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-02-13.
Collapse
Affiliation(s)
- I Fukada
- Breast Medical Oncology, Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research; Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Breast Oncology Center, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research
| | - K Araki
- Breast Medical Oncology, Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research; Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Breast Oncology Center, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research
| | - K Kobayashi
- Breast Medical Oncology, Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research; Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Breast Oncology Center, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research
| | - N Gomi
- Breast Medical Oncology, Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research; Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Breast Oncology Center, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research
| | - R Horii
- Breast Medical Oncology, Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research; Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Breast Oncology Center, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research
| | - F Akiyama
- Breast Medical Oncology, Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research; Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Breast Oncology Center, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research
| | - S Takahashi
- Breast Medical Oncology, Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research; Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Breast Oncology Center, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research
| | - T Iiwase
- Breast Medical Oncology, Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research; Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Breast Oncology Center, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research
| | - S Ohno
- Breast Medical Oncology, Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research; Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Breast Oncology Center, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research
| | - Y Ito
- Breast Medical Oncology, Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Division of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research; Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research; Breast Oncology Center, The Cancer Institute Hospital of The Japanese Foundation for Cancer Research
| |
Collapse
|
187
|
Kobayashi T, Nakano K, Tomomatsu J, Nara E, Ito Y, Kobayashi K, Fukada I, Araki K, Shimomura A, Shimoi T, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Nakamura K, Kotani N, Inatani M, Tamura K, Takahashi S. Abstract P3-14-10: Phase Ia/Ib study of taselisib (GDC-0032), a potent and selective phosphoinositide 3-kinase inhibitor, in Japanese patients with advanced solid tumors or hormone receptor-positive locally advanced or metastatic breast cancer (JO29196 study). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-14-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Taselisib (GDC-0032) is an orally bioavailable, potent and selective phosphoinositide 3-kinase (PI3K) inhibitor. Preclinical data showed that taselisib had increased antitumor activity against PIK3CA (gene encoding the PI3Kα isoform) mutant tumors. This study aimed to investigate the safety, tolerability and pharmacokinetics (PK) of taselisib as monotherapy and in combination with fulvestrant in Japanese patients (pts).
Materials and methods:
A 3+3 design was used. In Phase Ia, pts with advanced solid tumors received taselisib tablet monotherapy (2, 4 or 6 mg once daily [QD]), and safety and PK were evaluated. In Phase Ib, pts with hormone receptor-positive locally advanced or metastatic breast cancer received taselisib (2 or 4 mg QD) in combination with fulvestrant (500 mg at a time), and safety and PK were evaluated. Maximal administered doses of 6 mg QD as a single agent and 4 mg QD in combination with fulvestrant were based upon prior clinical trial experience with taselisib (Juric D. et al. AACR 2013, Abstract LB-64; Juric D. et al. SABCS 2013, Abstract PD1-3).
Results:
As of 15 Mar 2015, 9 pts (PIK3CA mutant: 2 pts) were enrolled in Phase Ia and 3 pts in Phase Ib. Phase Ia dose-escalation study has been completed and Phase Ib is ongoing.
In Phase Ia, no dose-limiting toxicity (DLT) was observed at any dose level tested (maximum administered dose of 6 mg QD). Common (≥3 pts) adverse reactions (ARs) were stomatitis (4 pts), rash (3 pts) and diarrhea (3 pts); the only Grade ≥3 AR was neutropenia (1 pt). Partial response was observed in 1 pt who received taselisib 4 mg and had a PIK3CA mutant breast tumor. Stable disease was observed in 4 pts. Cmax and AUC indicated a dose-proportional PK profile of taselisib within the dose range tested. Moreover, taselisib PK in Japanese pts was consistent with the PK reported from North American and European pts (Juric D. et al. AACR 2013, Abstract LB-64).
In Phase Ib, 3 pts received taselisib 2 mg in combination with fulvestrant and no DLT was observed. Preliminary ARs were similar to those with monotherapy and no Grade ≥3 AR was reported. Confirmation of tolerability of taselisib 4 mg in combination with fulvestrant is under evaluation.
Conclusion:
Taselisib monotherapy was well tolerated in Japanese pts up to a dose of 6 mg, which is the recommended dose in non-Japanese pts. Promising preliminary activity of monotherapy was observed in advanced solid tumors, especially in a pt with PIK3CA mutant tumor. The combination of taselisib 2 mg with fulvestrant is well tolerated. Investigation of tolerability of taselisib 4 mg in combination with fulvestrant is ongoing. Final results of this study will be presented here at the Symposium this year.
Citation Format: Kobayashi T, Nakano K, Tomomatsu J, Nara E, Ito Y, Kobayashi K, Fukada I, Araki K, Shimomura A, Shimoi T, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Nakamura K, Kotani N, Inatani M, Tamura K, Takahashi S. Phase Ia/Ib study of taselisib (GDC-0032), a potent and selective phosphoinositide 3-kinase inhibitor, in Japanese patients with advanced solid tumors or hormone receptor-positive locally advanced or metastatic breast cancer (JO29196 study). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-14-10.
Collapse
Affiliation(s)
- T Kobayashi
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - K Nakano
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - J Tomomatsu
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - E Nara
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - Y Ito
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - K Kobayashi
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - I Fukada
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - K Araki
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - A Shimomura
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - T Shimoi
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - M Kodaira
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - M Yunokawa
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - K Yonemori
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - C Shimizu
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - K Nakamura
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - N Kotani
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - M Inatani
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - K Tamura
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| | - S Takahashi
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
| |
Collapse
|
188
|
Miyoshi N, Kundu SK, Tuziuti T, Yasui K, Shimada I, Ito Y. Combination of Sonodynamic and Photodynamic Therapy against Cancer Would Be Effective through Using a Regulated Size of Nanoparticles. Nanosci Nanoeng 2016; 4:1-11. [PMID: 27088115 PMCID: PMC4827930 DOI: 10.13189/nn.2016.040101] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Nanoparticles have been used for many functional materials in nano-sciences and photo-catalyzing surface chemistry. The titanium oxide nanoparticles will be useful for the treatment of tumor by laser and/or ultrasound as the sensitizers in nano-medicine. We have studied the combination therapy of photo- and sono-dynamic therapies in an animal tumor model. Oral-administration of two sensitizers titanium oxide, 0.2%-TiO2 nanoparticles for sono-dynamic and 1 mM 5-aminolevulinic acid for photodynamic therapies have resulted in the best combination therapeutic effects for the cancer treatment. Our light microscopic and Raman spectroscopic studies revealed that the titanium nanoparticles were distributed inside the blood vessel of the cancer tissue (1-3 μm sizes). Among these nanoparticles with a broad size distribution, only particular-sized particles could penetrate through the blood vessel of the cancer tissue, while other particles may only exhibit the side effects in the model mouse. Therefore, it may be necessary to separate the optimum size particles. For this purpose we have separated TiO2 nanoparticles by countercurrent chromatography with a flat coiled column (1.6 mm ID) immersed in an ultrasonic bath (42 KHz). Separation was performed with a two-phase solvent system composed of 1-butanol-acetic acid-water at a volume ratio of 4:1:5 at a flow rate of 0.1 ml/min. Countercurrent chromatographic separation yielded fractions containing particle aggregates at 31 and 4400 nm in diameter.
Collapse
Affiliation(s)
- N. Miyoshi
- Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, Japan
| | - S. K. Kundu
- Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, Japan
- Department of Pharmacy, Jahangirnagar University, Bangladesh
| | - T. Tuziuti
- National Institute of Advanced Industrial Science and Technology (NAIST), Japan
| | - K. Yasui
- National Institute of Advanced Industrial Science and Technology (NAIST), Japan
| | - I. Shimada
- Department of Forensic Medicine, Faculty of Medicine, University of Fukui, Japan
| | - Y. Ito
- Laboratory of Bioseparation Technology, Biochemistry and Biophysics Center, National Heart, Lung, and Blood Institute, USA
| |
Collapse
|
189
|
Nagaya K, Motomura K, Kukk E, Takahashi Y, Yamazaki K, Ohmura S, Fukuzawa H, Wada S, Mondal S, Tachibana T, Ito Y, Koga R, Sakai T, Matsunami K, Nakamura K, Kanno M, Rudenko A, Nicolas C, Liu XJ, Miron C, Zhang Y, Jiang Y, Chen J, Anand M, Kim DE, Tono K, Yabashi M, Yao M, Kono H, Ueda K. Femtosecond charge and molecular dynamics of I-containing organic molecules induced by intense X-ray free-electron laser pulses. Faraday Discuss 2016; 194:537-562. [DOI: 10.1039/c6fd00085a] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
We studied the electronic and nuclear dynamics of I-containing organic molecules induced by intense hard X-ray pulses at the XFEL facility SACLA in Japan. The interaction with the intense XFEL pulse causes absorption of multiple X-ray photons by the iodine atom, which results in the creation of many electronic vacancies (positive charges) via the sequential electronic relaxation in the iodine, followed by intramolecular charge redistribution. In a previous study we investigated the subsequent fragmentation by Coulomb explosion of the simplest I-substituted hydrocarbon, iodomethane (CH3I). We carried out three-dimensional momentum correlation measurements of the atomic ions created via Coulomb explosion of the molecule and found that a classical Coulomb explosion model including charge evolution (CCE-CE model), which accounts for the concerted dynamics of nuclear motion and charge creation/charge redistribution, reproduces well the observed momentum correlation maps of fragment ions emitted after XFEL irradiation. Then we extended the study to 5-iodouracil (C4H3IN2O2, 5-IU), which is a more complex molecule of biological relevance, and confirmed that, in both CH3I and 5-IU, the charge build-up takes about 10 fs, while the charge is redistributed among atoms within only a few fs. We also adopted a self-consistent charge density-functional based tight-binding (SCC-DFTB) method to treat the fragmentations of highly charged 5-IU ions created by XFEL pulses. Our SCC-DFTB modeling reproduces well the experimental and CCE-CE results. We have also investigated the influence of the nuclear dynamics on the charge redistribution (charge transfer) using nonadiabatic quantum-mechanical molecular dynamics (NAQMD) simulation. The time scale of the charge transfer from the iodine atomic site to the uracil ring induced by nuclear motion turned out to be only ∼5 fs, indicating that, besides the molecular Auger decay in which molecular orbitals delocalized over the iodine site and the uracil ring are involved, the nuclear dynamics also play a role for ultrafast charge redistribution. The present study illustrates that the CCE-CE model as well as the SCC-DFTB method can be used for reconstructing the positions of atoms in motion, in combination with the momentum correlation measurement of the atomic ions created via XFEL-induced Coulomb explosion of molecules.
Collapse
|
190
|
Oguri T, Kunii E, Fukuda S, Uemura T, Takakuwa O, Maeno K, Kanemitsu Y, Ohkubo H, Takemura M, Ito Y, Niimi A. 8P Organic cation transporter 6 directly confers resistance to anticancer platinum drugs. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv517.08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
191
|
Natsume J, Ogawa C, Fukasawa T, Yamamoto H, Ishihara N, Sakaguchi Y, Ito Y, Takeuchi T, Azuma Y, Ando N, Kubota T, Tsuji T, Kawai H, Naganawa S, Kidokoro H. White Matter Abnormality Correlates with Developmental and Seizure Outcomes in West Syndrome of Unknown Etiology. AJNR Am J Neuroradiol 2015; 37:698-705. [PMID: 26585267 DOI: 10.3174/ajnr.a4589] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2015] [Accepted: 08/26/2015] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE West syndrome is an epileptic encephalopathy characterized by epileptic spasms, a specific pattern on electroencephalography of hypsarrhythmia, and developmental regression. Our aim was to assess white matter abnormalities in West syndrome of unknown etiology. We hypothesized that diffusion tensor imaging reveals white matter abnormalities, especially in patients with poor seizure and developmental outcomes. MATERIALS AND METHODS We enrolled 23 patients with new-onset West syndrome of unknown etiology. DTI was performed at 12 and 24 months of age. Fractional anisotropy images were compared with those of controls by using tract-based spatial statistics. We compared axial, radial, and mean diffusivity between patients and controls in the fractional anisotropy skeleton. We determined correlations of these parameters with developmental quotient, electroencephalography, and seizure outcomes. We also compared DTI with hypometabolism on fluorodeoxyglucose positron-emission tomography. RESULTS At 12 months of age, patients showed widespread fractional anisotropy reductions and higher radial diffusivity in the fractional anisotropy skeleton with a significant difference on tract-based spatial statistics. The developmental quotient at 12 months of age correlated positively with fractional anisotropy and negatively with radial and mean diffusivity. Patients with seizure and abnormal findings on electroencephalography after initial treatments had lower fractional anisotropy and higher radial diffusivity. At 24 months, although tract-based spatial statistics did not show significant differences between patients and controls, tract-based spatial statistics in the 10 patients with a developmental quotient of <70 had significant fractional anisotropy reduction. In patients with unilateral temporal lobe hypometabolism on PET, tract-based spatial statistics showed greater fractional anisotropy reduction in the temporal lobe ipsilateral to the side of PET hypometabolism. CONCLUSIONS Diffuse abnormal findings on DTI at 12 months of age suggest delayed myelination as a key factor underlying abnormal findings on DTI. Conversely, asymmetric abnormal findings on DTI at 24 months may reflect underlying focal pathologies.
Collapse
Affiliation(s)
- J Natsume
- From the Departments of Pediatrics (J.N., C.O., H.Y., N.I., Y.S., Y.I., T. Takeuchi, Y.A., H. Kidokoro) Developmental Disability Medicine (J.N.) Brain and Mind Research Center (J.N., H. Kidokoro), Nagoya University, Nagoya, Japan
| | - C Ogawa
- From the Departments of Pediatrics (J.N., C.O., H.Y., N.I., Y.S., Y.I., T. Takeuchi, Y.A., H. Kidokoro)
| | - T Fukasawa
- Department of Pediatrics (T.F., T.K.), Anjo Kosei Hospital, Anjo, Japan
| | - H Yamamoto
- From the Departments of Pediatrics (J.N., C.O., H.Y., N.I., Y.S., Y.I., T. Takeuchi, Y.A., H. Kidokoro)
| | - N Ishihara
- From the Departments of Pediatrics (J.N., C.O., H.Y., N.I., Y.S., Y.I., T. Takeuchi, Y.A., H. Kidokoro)
| | - Y Sakaguchi
- From the Departments of Pediatrics (J.N., C.O., H.Y., N.I., Y.S., Y.I., T. Takeuchi, Y.A., H. Kidokoro)
| | - Y Ito
- From the Departments of Pediatrics (J.N., C.O., H.Y., N.I., Y.S., Y.I., T. Takeuchi, Y.A., H. Kidokoro)
| | - T Takeuchi
- From the Departments of Pediatrics (J.N., C.O., H.Y., N.I., Y.S., Y.I., T. Takeuchi, Y.A., H. Kidokoro)
| | - Y Azuma
- From the Departments of Pediatrics (J.N., C.O., H.Y., N.I., Y.S., Y.I., T. Takeuchi, Y.A., H. Kidokoro)
| | - N Ando
- Department of Pediatrics and Neonatology (N.A.), Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
| | - T Kubota
- Department of Pediatrics (T.F., T.K.), Anjo Kosei Hospital, Anjo, Japan
| | - T Tsuji
- Department of Pediatrics (T. Tsuji), Okazaki City Hospital, Okazaki, Japan
| | - H Kawai
- Radiology (H. Kawai, S.N.), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - S Naganawa
- Radiology (H. Kawai, S.N.), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - H Kidokoro
- From the Departments of Pediatrics (J.N., C.O., H.Y., N.I., Y.S., Y.I., T. Takeuchi, Y.A., H. Kidokoro) Brain and Mind Research Center (J.N., H. Kidokoro), Nagoya University, Nagoya, Japan
| |
Collapse
|
192
|
Motomura K, Izumi T, Tateishi S, Tamaki Y, Ito Y, Horinouchi T, Nakanishi K. Superparamagnetic iron oxide-enhanced MRI at 3 T for accurate axillary staging in breast cancer. Br J Surg 2015; 103:60-9. [PMID: 26572241 DOI: 10.1002/bjs.10040] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2015] [Revised: 05/08/2015] [Accepted: 09/25/2015] [Indexed: 12/28/2022]
Abstract
BACKGROUND The aim of this study was to evaluate whether MRI at 3 T with superparamagnetic iron oxide (SPIO) enhancement is an accurate and useful method for detecting metastases in sentinel nodes identified by CT-lymphography (CT-LG) in patients with breast cancer. The results were compared with those obtained using CT-LG alone and diagnosing metastasis according to size criteria. METHODS Patients with clinically node-negative breast cancer were included. Sentinel nodes identified by CT-LG were evaluated prospectively using SPIO-enhanced MRI at 3 T. Sentinel node size was measured on CT-LG, and a node larger than 5 mm in short-axis diameter was considered metastatic. Sentinel nodes localized by CT-LG were removed, and imaging results and histopathological findings were compared. RESULTS Sentinel nodes were identified successfully by CT-LG in 69 (99 per cent) of 70 patients. All 19 patients with a finding of metastasis in sentinel nodes at pathology were also shown to have metastases on MRI. Forty-eight of 50 patients with non-metastatic sentinel nodes diagnosed at pathology were classified as having non-metastatic nodes on MRI. On a patient-by-patient basis, the sensitivity, specificity and accuracy of MRI for the diagnosis of sentinel node metastases were 100, 96 and 97 per cent; respective values for CT-LG were 79, 56 and 62 per cent. The specificity and accuracy of MRI were superior to those of CT-LG (P < 0·001 and P = 0·002 respectively). CONCLUSION SPIO-enhanced MRI at 3 T is useful for accurate diagnosis of metastatic sentinel nodes, indicating that sentinel node biopsy may be avoided in patients with breast cancer who have non-metastatic sentinel nodes on imaging.
Collapse
Affiliation(s)
- K Motomura
- Departments of Breast and Endocrine Surgery, Osaka Medical Centre for Cancer and Cardiovascular Diseases, Osaka, Japan
| | - T Izumi
- Departments of Radiology, Osaka Medical Centre for Cancer and Cardiovascular Diseases, Osaka, Japan
| | - S Tateishi
- Departments of Radiology, Osaka Medical Centre for Cancer and Cardiovascular Diseases, Osaka, Japan
| | - Y Tamaki
- Departments of Breast and Endocrine Surgery, Osaka Medical Centre for Cancer and Cardiovascular Diseases, Osaka, Japan
| | - Y Ito
- Centre for Cancer Control and Statistics, Osaka Medical Centre for Cancer and Cardiovascular Diseases, Osaka, Japan
| | - T Horinouchi
- Departments of Radiology, Osaka Medical Centre for Cancer and Cardiovascular Diseases, Osaka, Japan
| | - K Nakanishi
- Departments of Radiology, Osaka Medical Centre for Cancer and Cardiovascular Diseases, Osaka, Japan
| |
Collapse
|
193
|
Ito Y, Murakami N, Inaba K, Takahashi K, Umezawa R, Igaki H, Sekii S, Harada K, Kitaguchi M, Kobayashi K, Kashihara T, Yoshimoto S, Itami J. Treatment Outcomes of Intensity Modulated Radiation Therapy for Clinical Stage I/II Hypopharyngeal Cancer. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
194
|
Onishi H, Onimaru R, Shibata T, Hiraoka M, Ishikura S, Karasawa K, Matsuo Y, Kokubo M, Shioyama Y, Matsushita H, Ito Y, Shirato H. Dose-Escalation Study of Stereotactic Body Radiation Therapy (SBRT) for Peripheral T2N0M0 Non-Small Cell Lung Cancer (NSCLC) With PTV ≥ 100 cm3: Japan Clinical Oncology Group Study (JCOG0702). Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.244] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
195
|
Endo N, Rahayu LP, Ito Y, Tanaka T. Ovarian and hormonal responses to single or continuous peripheral administration of senktide, a neurokinin 3 receptor agonist, during the follicular phase in goats. Domest Anim Endocrinol 2015; 53:136-43. [PMID: 26295982 DOI: 10.1016/j.domaniend.2015.07.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/27/2015] [Revised: 07/16/2015] [Accepted: 07/19/2015] [Indexed: 10/23/2022]
Abstract
The present study aimed to investigate the effects of single or continuous administration of a neurokinin 3 receptor agonist, senktide, on hormonal and follicular dynamics in follicular phase goats. Goats were injected with PGF2α in the luteal phase and treated with an intravaginal progesterone device for 10 d. At 12 h after the cessation of progesterone treatment, the goats received a single intravenous injection of senktide (200 nmol, n = 4) or vehicle (n = 4), or continuous intravenous infusion of senktide (20 nmol/min, n = 6) or vehicle (n = 6) for 6 h. Blood sampling and ovarian ultrasonography were performed during the experiment. A single injection of senktide did not influence the number of luteinizing hormone (LH) pulses and mean LH concentration. On the other hand, continuous injection of senktide caused a sustained increase in LH secretion, and mean LH concentration in samples collected at 10-min intervals for 6 h after the start of infusion was higher than that of vehicle-treated goats (2.8 ± 1.3 vs 1.0 ± 0.6 ng/mL, P < 0.01). In 4 of 6 goats, LH concentrations reached their peaks during the 6-h senktide infusion, and ovulation was observed at 48 h after the start of infusion without estrous behavior. The remaining 2 senktide-treated goats and all vehicle-treated goats showed estrus and ovulated at 72 or 96 h after treatment. These results suggest that continuous infusion of senktide in follicular phase goats can cause a sustained increase in LH and advance the time of ovulation.
Collapse
Affiliation(s)
- N Endo
- Laboratory of Veterinary Reproduction, Tokyo University of Agriculture and Technology, Fuchu, Tokyo, 183-8509, Japan; United Graduate School of Veterinary Sciences, Gifu University, Gifu, 501-1193, Japan
| | - L P Rahayu
- Laboratory of Veterinary Reproduction, Tokyo University of Agriculture and Technology, Fuchu, Tokyo, 183-8509, Japan; United Graduate School of Veterinary Sciences, Gifu University, Gifu, 501-1193, Japan
| | - Y Ito
- Laboratory of Veterinary Reproduction, Tokyo University of Agriculture and Technology, Fuchu, Tokyo, 183-8509, Japan
| | - T Tanaka
- Laboratory of Veterinary Reproduction, Tokyo University of Agriculture and Technology, Fuchu, Tokyo, 183-8509, Japan; United Graduate School of Veterinary Sciences, Gifu University, Gifu, 501-1193, Japan.
| |
Collapse
|
196
|
Tsukutani Y, Hagino H, Ito Y, Nagashima H. Epidemiology of fragility fractures in Sakaiminato, Japan: incidence, secular trends, and prognosis. Osteoporos Int 2015; 26:2249-55. [PMID: 25986382 DOI: 10.1007/s00198-015-3124-z] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/18/2014] [Accepted: 03/31/2015] [Indexed: 01/19/2023]
Abstract
UNLABELLED We investigated the incidence of fragility fractures from 2010 to 2012 in Sakaiminato, Japan. The incidence rates of limb fractures in Sakaiminato were lower than in Caucasian populations but had increased relative to data obtained in Japan in the 1990s. Clinical vertebral fractures occurred at higher rates in Sakaiminato than in Caucasian populations. INTRODUCTION To elucidate the incidence and prognosis of fragility fractures in Sakaiminato, Japan. METHODS A survey of all hip, distal radius, proximal humerus, and clinical vertebral fractures was performed from 2010 to 2012 in patients aged 50 or older in Sakaiminato city, Tottori prefecture, Japan. The age- and gender-specific incidence rates (per 100,000 person-years) were calculated based on the population of Sakaiminato city each year. The incidence rates of hip, distal radius, and proximal humerus fractures were compared with previous reports. We conducted a follow-up study assessing patients within 1 year following their initial treatment at two Sakaiminato hospitals. RESULTS The age-adjusted incidence rates in population aged 50 years or older (per 100,000 person-years) of hip, distal radius, proximal humerus, and clinical vertebral fractures were, respectively, 217, 82, 26, and 412 in males and 567, 432, 96, and 1229 in females. Age-specific incidence rates of hip, distal radius, and proximal humerus fractures all increased since the 1990s. Our study also revealed that anti-osteoporotic pharmacotherapy was prescribed 1 year post-fracture at rates of 29, 20, 30, and 50 % for patients with hip, distal radius, proximal humerus, and clinical vertebral fractures, respectively. CONCLUSIONS The incidence rates of limb fractures in Sakaiminato were substantially lower than Caucasian populations in northern Europe but had increased relative to data obtained in Japan in the 1990s. Unlike upper and lower limb fractures, clinical vertebral fractures occurred at higher rates in our study population than in other Asian and North European countries.
Collapse
Affiliation(s)
- Y Tsukutani
- Department of Orthopedic Surgery, Faculty of Medicine, Tottori University, 36-1 Nishi-Cho, Yonago, Tottori, 683-8504, Japan,
| | | | | | | |
Collapse
|
197
|
Takakura T, Mukumoto N, Higuchi D, Ito Y, Nakayasu N, Ito H, Sakamoto T. 625 Optimal imaging conditions in the planning of dynamic tracking SBRT. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30361-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
198
|
Guy AT, Nagatsuka Y, Ooashi N, Inoue M, Nakata A, Greimel P, Inoue A, Nabetani T, Murayama A, Ohta K, Ito Y, Aoki J, Hirabayashi Y, Kamiguchi H. Glycerophospholipid regulation of modality-specific sensory axon guidance in the spinal cord. Science 2015; 349:974-7. [DOI: 10.1126/science.aab3516] [Citation(s) in RCA: 72] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
199
|
Hanley SJB, Yoshioka E, Ito Y, Kishi R. Department of Error. Lancet 2015; 386:248. [PMID: 26194527 DOI: 10.1016/s0140-6736(15)61280-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
200
|
Kotani K, Tsuzaki K, Ito Y, Sakane N. Correlation between the methods for high-density lipoprotein subfraction analyses: An electrophoretic method and a homogeneous assay method. Atherosclerosis 2015. [DOI: 10.1016/j.atherosclerosis.2015.04.426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|